Updated clinical data on RLY-2608 plus fulvestrant will be presented at the San Antonio Breast Cancer Symposium, showcasing its efficacy in advanced breast cancer.

An IARC-led randomized controlled trial is evaluating an AI-powered chatbot to increase cervical cancer screening among women.

BRUKINSA demonstrated a 71% reduction in progression or death risk compared to bendamustine-rituximab in treatment-naïve CLL patients over a 5-year follow-up.

A Phase II trial (RAMOSE) demonstrated that combining osimertinib and ramucirumab significantly prolonged progression-free survival (PFS) in patients with EGFR-mutant, TKI-naïve NSCLC.

Preliminary Phase 1b data of vepdegestrant with abemaciclib shows a 62.5% clinical benefit rate in advanced breast cancer patients previously treated with CDK4/6 inhibitors.

Wayne State University enrolled the first Michigan patient in a Phase I/II trial testing stem cell-derived interneuron implantation to reduce seizure frequency.

Eli Lilly plans to launch tirzepatide, known as Mounjaro and Zepbound, in India by 2025 for diabetes and obesity treatment, pending regulatory approvals.

The NATALEE trial demonstrated that ribociclib, at a 400-mg dose, presents a manageable safety profile for patients with HR+ early breast cancer, with neutropenia being the most common toxicity.

The ProstACT GLOBAL trial is evaluating 177Lu-TLX591 plus standard of care (SOC) versus SOC alone in metastatic castration-resistant prostate cancer (mCRPC) patients.

Combination therapy with SHR-1701 and famitinib demonstrates encouraging objective response rates in biliary tract cancer (BTC) and pancreatic ductal adenocarcinoma (PDAC) patients.

Disitamab Vedotin (DV) significantly improved progression-free survival (PFS) compared to Lapatinib plus Capecitabine in HER2-positive advanced breast cancer with liver metastasis.

Novartis' intrathecal onasemnogene abeparvovec (OAV101 IT) met its primary endpoint in the Phase III STEER study for SMA Type 2.

A study of type 2 diabetes patients not on bolus insulin showed that continuous glucose monitoring (CGM) significantly improved glycemic control compared to standard care.

The European Commission has granted marketing authorization for imetelstat (Rytelo) as the first telomerase inhibitor approved for transfusion-dependent anemia in lower-risk myelodysplastic syndrome patients ineligible for or unresponsive to erythropoietin-based therapy.

A meta-analysis of seven RCTs demonstrates that fezolinetant and elinzanetant significantly reduce the frequency of vasomotor symptoms in menopausal women.

A groundbreaking clinical trial is investigating the effectiveness of stabilizing benzodiazepine agonist treatment compared to standard tapering for patients with benzodiazepine dependence in opioid agonist treatment (OAT) programs. The 26-week study will evaluate treatment outcomes across multiple Norwegian OAT clinics, with a primary focus on reducing illicit benzodiazepine use.

A recent study indicates that empagliflozin is associated with a 22% lower risk of diabetic retinopathy progression in type 2 diabetes patients.

Psilocybin-assisted psychotherapy significantly reduced anxiety, depression, and other psychological distress in cancer patients, with benefits lasting up to six months.

A recent study found that switching from entecavir (ETV) to tenofovir alafenamide (TAF) in chronic hepatitis B patients showed similar effects on serum HBsAg levels over 240 weeks.